ALPHA TAU MEDICAL LTD

Explore Alpha Tau Medical CFO Levy Raphi’s latest round‑trip trade—buying at $2.98, selling at $14.00—to gauge insider confidence and future upside potential.

Alpha Tau Medical CFO buys 17,873 shares at $2.98, a discount to $13.19, signalling confidence in the company’s oncology device growth and potential upside.

Alpha Tau Medical’s CFO sells 20,000 shares: learn how this insider move signals potential confidence shifts and what it means for investors.

Alpha Tau CFO’s bulk sales amid a 30 % stock surge: why insider selling may signal personal wealth moves, not company trouble, and how the firm’s growing alpha‑emitter tech and regulatory wins keep its upside intact.

Alpha Tau Medical’s CFO sales boost buzz while the firm’s beta‑emitter oncology drug shows promising Phase‑II results and fast‑track orphan‑drug status, hinting at strong future growth.

Alpha Tau Medical insider sales show short‑term profit‑taking amid rising share prices and strong clinical milestones—a buying opportunity for savvy investors.

Alpha Tau CFO sells shares amid 40% monthly jump; insider sale at $10.80 reflects confidence in Tolmar partnership, Alpha DaRT® launch and bullish outlook.

Alpha Tau Medical’s insider activity signals strong confidence in its alpha‑radiation oncology platform, revealing growth prospects and potential dilution risks for investors.